Navigation Links
Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
Date:11/7/2013

BURLINGTON, Mass., Nov. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed medical oncologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) currently prescribe Roche/Genentech's targeted agent Herceptin (with or without chemotherapy and/or hormonal therapy) to an average of half or more of their first-line HER2+ advanced breast cancer patients. Considering likely funding or reimbursement restrictions, respondents expect their prescribing of Roche/Genentech's Perjeta—which was approved in March 2013—in combination with Herceptin, will increase substantially from an average of no more than 12 percent of such patients currently to around one-quarter of patients in most countries by the end of 2016.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The new European Physician and Payer Forum report entitled Tightening Healthcare Budgets and Elevated Cost-Effectiveness Expectations: How Will Payers and Prescribers Prioritize Targeted Agents for Breast Cancer in the EU5? also finds that although half or more surveyed oncologists expect that Roche/Genentech's emerging HER2-targeting antibody drug conjugate Kadcyla in combination with Perjeta will likely demonstrate a significant efficacy benefit over single agent Kadcyla or Herceptin with chemotherapy in the advanced HER2+ first-line setting, less than 40 percent of respondents across the EU5 expect premium-priced Kadcyla/Perjeta combination is likely to be reimbursed in their country or region. Collectively, those surveyed a
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Unchained Labs, a refreshingly ... this year,s PEGS conference and launches the UNit — ... biologics. PEGS: The Essential Protein Engineering Summit takes place ... The UNit lets drug discovery researchers look ... out there. Its 7 applications, 144 sample a day ...
(Date:5/4/2015)...  Geneia, a company of experienced healthcare change ... healthcare efficiencies, today announced a first-of-its-kind partnership with ... use Geneia,s advanced analytics solution coupled with its ... lower the cost of patient care. ... utilization data from multiple sources to create a ...
(Date:5/4/2015)... Ohio , May 4, 2015 The ... Workforce Survey, which confirmed that pharmacy has shifted toward ... as active pharmacists and managers, there is an incredible ... pharmacists in the next decade. In ... leadership site, Essential Insights , Eden Sulzer, ...
Breaking Medicine Technology:Unchained Labs Lets the UNit Loose 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 3
... Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company ... financial results for the three months ended September 30, ... 2009 , As of September 30, 2009, Orexigen ... an additional $50.9 million in investment securities, available-for-sale. ...
... , FRANKLIN, Mass., Nov. 4 Echo Therapeutics, Inc. ... the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, ... SkinPrep System for transdermal drug delivery announced today that ... Transdermal Continuous Glucose Monitoring System (tCGM System) in patients ...
Cached Medicine Technology:Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 2Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 3
(Date:5/4/2015)... 04, 2015 Now in its seventh ... leaders who have made outstanding contributions to the company, ... both in acute and post-acute care settings. The five ... Provider of the Year, Advanced Practice Clinician of the ... of the Year. Recipients are selected by IPC’s senior ...
(Date:5/4/2015)... May 04, 2015 EyeCRO LLC and ... to facilitate development of NM108, a first-in-class small molecule ... to blindness, including Diabetic Retinopathy. The collaboration grants ... by EyeCRO, which can deliver drugs to the front ... , Under the terms of the agreement, EyeCRO ...
(Date:5/4/2015)... 04, 2015 Ticket Down is a reputable ... Life Arena in Columbia, South Carolina. Fans of ... his “Out There” tour which originally kicked off in 2013. ... North America and the legendary performer recently announced that he ... Fargo Arena on June 21st, in Charlottesville, VA at John ...
(Date:5/4/2015)... Pricing Healthcare announces it will be ... receiving care at St. George Surgical Center in ... performed by July 15th, 2015, and the patient must be ... and forego the filing of insurance claims). , The healthcare ... and it devastates more and more individuals and families. ...
(Date:5/4/2015)... Atlanta, GA (PRWEB) May 04, 2015 ... in Atlanta, Georgia proudly offers the latest non-surgical double-chin ... the only facial plastic surgeon in Atlanta to offer ... Kybella drug to be injected specifically under the chin, ... ‘double-chin’ appearance. , Before Kybella, patients who sought immediate ...
Breaking Medicine News(10 mins):Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2
... ... , ... ... NEW YORK , March 12 In releasing a new report on maternal health nationwide, Amnesty International today ...
... Md. , March 11 Micromet, Inc. (Nasdaq: ... of 10 million shares of common stock at a public offering ... the underwriters a 30-day option to purchase an additional 1.5 million ... in the offering are being sold by Micromet.  The closing of ...
... By ... patients, Sarasota Memorial Urologist Robert Carey, MD, hopes more surgeons will embrace less invasive ... ... most common treatment for renal cell cancer, a type of cancer typically resistant to ...
... KINGWOOD, Texas , March 11 International Merchant Advisors, ... will appear live on the Bill Chippas show ... . Mr. Roseman,s interview will follow Rush Limbaugh ,s regular ... Florida earlier today. Mr. Roseman,s interview will cover the company,s ...
... the area of the brain called the hippocampus may ... scientists have suspected, than with an active decision-making process, ... University and the University of Minnesota Medical School. In ... found that replays occurring in the hippocampus were not ...
... Device works on skin lesions caused by parasite in ... News) -- Heat therapy is effective for treating lesions ... soldiers in Iraq and Afghanistan, a new study shows. ... than 1,300 American military and civilian personnel have developed ...
Cached Medicine News:Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Louisiana is 46th Among All States in Maternal Mortality 2Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Louisiana is 46th Among All States in Maternal Mortality 3Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Louisiana is 46th Among All States in Maternal Mortality 4Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Louisiana is 46th Among All States in Maternal Mortality 5Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Louisiana is 46th Among All States in Maternal Mortality 6Health News:Micromet Announces Pricing of Public Offering of 10 Million Shares of Common Stock 2Health News:Micromet Announces Pricing of Public Offering of 10 Million Shares of Common Stock 3Health News:Micromet Announces Pricing of Public Offering of 10 Million Shares of Common Stock 4Health News:Florida Surgeon Demonstrates Kidney Sparing Cancer Treatment in Live Surgical Webcast 2Health News:Florida Surgeon Demonstrates Kidney Sparing Cancer Treatment in Live Surgical Webcast 3Health News:Florida Surgeon Demonstrates Kidney Sparing Cancer Treatment in Live Surgical Webcast 4Health News:International Merchant Advisors CEO Mel Roseman to Discuss New Wellness Centers and Medical Marijuana Clinic Acquisitions Program Live on Bill Chippas Show Today, March 11th at 6:20 pm EST 2Health News:International Merchant Advisors CEO Mel Roseman to Discuss New Wellness Centers and Medical Marijuana Clinic Acquisitions Program Live on Bill Chippas Show Today, March 11th at 6:20 pm EST 3Health News:Carnegie Mellon research provides insight into brain's decision-making process 2Health News:Carnegie Mellon research provides insight into brain's decision-making process 3
... to three conventional measurement modes (Phakic, Aphakic, ... a new axial length measuring mode. Normal ... sonic velocity for conversion at 1550m/s. The ... calculating each tissues sonic velocity for conversion: ...
... A-Scan/Pachymeter with graphic display and IOL ... A-Scan/Pachymeter combination units include firmware module ... Binkhorst II formulas. Audible tones increase ... to visual axis. Constant tone when ...
... the world's first very high frequency digital ... technology, Artemis provides microscopic resolution images and ... anterior segments of the human eye. Artemis ... eye scanner. In use, the patient leans ...
... The ISYSTEM-ABD ("I-cubed") is an ... featuring an analog oscilloscope (static deflection) ... and resolution than low cost video ... hyaloid, syneresis, inflammatory cells, as well ...
Medicine Products: